161 related articles for article (PubMed ID: 19303940)
1. Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein.
Dallinga-Thie GM; van Tol A; Dullaart RP;
Biochim Biophys Acta; 2009 Aug; 1791(8):714-8. PubMed ID: 19303940
[TBL] [Abstract][Full Text] [Related]
2. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
[TBL] [Abstract][Full Text] [Related]
3. Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients.
Riemens SC; van Tol A; Sluiter WJ; Dullaart RP
Diabetologia; 1998 Aug; 41(8):929-34. PubMed ID: 9726595
[TBL] [Abstract][Full Text] [Related]
4. A low-saturated-fat, low-cholesterol diet decreases plasma CETP activity and pre beta-HDL formation but does not affect cellular cholesterol efflux to plasma from type 1 diabetic patients.
De Vries R; Beusekamp BJ; Kerstens MN; Groen AK; Van Tol A; Dullaart RP
Scand J Clin Lab Invest; 2005; 65(8):729-37. PubMed ID: 16319046
[TBL] [Abstract][Full Text] [Related]
5. Plasma phospholipid transfer protein activity is inversely associated with betaine in diabetic and non-diabetic subjects.
Dullaart RP; Garcia E; Jeyarajah E; Gruppen EG; Connelly MA
Lipids Health Dis; 2016 Aug; 15(1):143. PubMed ID: 27581838
[TBL] [Abstract][Full Text] [Related]
6. Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification.
de Vries R; Groen AK; Perton FG; Dallinga-Thie GM; van Wijland MJ; Dikkeschei LD; Wolffenbuttel BH; van Tol A; Dullaart RP
Atherosclerosis; 2008 Feb; 196(2):733-41. PubMed ID: 17275009
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein M predicts pre-beta-HDL formation: studies in type 2 diabetic and nondiabetic subjects.
Plomgaard P; Dullaart RP; de Vries R; Groen AK; Dahlbäck B; Nielsen LB
J Intern Med; 2009 Sep; 266(3):258-67. PubMed ID: 19457058
[TBL] [Abstract][Full Text] [Related]
8. Plasma phospholipid transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E?
Dallinga-Thie GM; van Tol A; Hattori H; Rensen PC; Sijbrands EJ
Diabetes; 2006 May; 55(5):1491-6. PubMed ID: 16644710
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin affects low density lipoprotein and non-high density lipoprotein cholesterol relations with apolipoprotein B in type 2 diabetes mellitus: modification by triglycerides and cholesteryl ester transfer protein.
Kappelle PJ; Zwang L; Huisman MV; Banga JD; Sluiter WJ; Dallinga-Thie GM; Dullaart RP
Expert Opin Ther Targets; 2009 Jul; 13(7):743-51. PubMed ID: 19505224
[TBL] [Abstract][Full Text] [Related]
10. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets.
Kappelle PJ; Dallinga-Thie GM; Dullaart RP;
Biochim Biophys Acta; 2010 Jan; 1801(1):89-94. PubMed ID: 19800983
[TBL] [Abstract][Full Text] [Related]
11. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs.
Briand F; Magot T; Krempf M; Nguyen P; Ouguerram K
Eur J Clin Invest; 2006 Apr; 36(4):224-30. PubMed ID: 16620283
[TBL] [Abstract][Full Text] [Related]
12. Pre-β-HDL formation relates to high-normal free thyroxine in type 2 diabetes mellitus.
van Tienhoven-Wind LJ; Perton FG; Dullaart RP
Clin Biochem; 2016 Jan; 49(1-2):41-6. PubMed ID: 26320015
[TBL] [Abstract][Full Text] [Related]
13. Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins.
Borggreve SE; De Vries R; Dullaart RP
Eur J Clin Invest; 2003 Dec; 33(12):1051-69. PubMed ID: 14636288
[TBL] [Abstract][Full Text] [Related]
14. Acute and chronic effects of a 24-hour intravenous triglyceride emulsion challenge on plasma lecithin: cholesterol acyltransferase, phospholipid transfer protein, and cholesteryl ester transfer protein activities.
Riemens SC; Van Tol A; Sluiter WJ; Dullaart RP
J Lipid Res; 1999 Aug; 40(8):1459-66. PubMed ID: 10428982
[TBL] [Abstract][Full Text] [Related]
15. Type 2 diabetes mellitus is associated with differential effects on plasma cholesteryl ester transfer protein and phospholipid transfer protein activities and concentrations.
Dullaart RP; De Vries R; Scheek L; Borggreve SE; Van Gent T; Dallinga-Thie GM; Ito M; Nagano M; Sluiter WJ; Hattori H; Van Tol A
Scand J Clin Lab Invest; 2004; 64(3):205-15. PubMed ID: 15222630
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides.
Dallinga-Thie GM; Berk-Planken II; Bootsma AH; Jansen H;
Diabetes Care; 2004 Jun; 27(6):1358-64. PubMed ID: 15161788
[TBL] [Abstract][Full Text] [Related]
17. Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in type 2 diabetes mellitus.
de Vries R; Dallinga-Thie GM; Smit AJ; Wolffenbuttel BH; van Tol A; Dullaart RP
Diabetologia; 2006 Feb; 49(2):398-404. PubMed ID: 16374627
[TBL] [Abstract][Full Text] [Related]
18. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes.
van Venrooij FV; Stolk RP; Banga JD; Sijmonsma TP; van Tol A; Erkelens DW; Dallinga-Thie GM;
Diabetes Care; 2003 Apr; 26(4):1216-23. PubMed ID: 12663600
[TBL] [Abstract][Full Text] [Related]
19. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
20. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice.
de Haan W; van der Hoogt CC; Westerterp M; Hoekstra M; Dallinga-Thie GM; Princen HM; Romijn JA; Jukema JW; Havekes LM; Rensen PC
Atherosclerosis; 2008 Mar; 197(1):57-63. PubMed ID: 17868678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
